Biological drugs, such as monoclonal antibodies and recombinant hormones and cytokines have revolutionised many different therapeutic indications, yielding multiple blockbuster drug products. However, although powerful in action, such biological drugs act systemically (on the whole organism) and offer little potential for targeted action at the site where therapeutic intervention is required. As a result, optimum use of such agents is usually hampered by unwanted side-effects. For example, anti-TNFs (e.g.: Humira) provide anti-inflammatory efficacy acting in the joints of patients with rheumatoid arthritis, however by acting systemically they increase the risk contracting infections and even of some forms of cancer.
Stealthyx has demonstrated that a naturally-occurring system that keeps one particular cytokine, called TGF-beta, in a latent form so that it can only act locally, can be deployed to deliver essentially any payload in a highly targeted manner. The Stealthyx platform provides the ability to take well-validated biological drugs and deliver improved versions which retain the local activity required for efficacy, while eliminating the systemic effects responsible for the undesirable side-effects. The flexible Stealthyx platform has the potential to allow essentially any desired activity profile to be engineered for any biologic drug.
Stealthyx aims to own a pipeline of high value therapeutic agents addressing large unmet medical needs. The company will do this by validating the Stealthyx platform for local delivery of biologic therapeutic candidates in a wide number of indications ranging from autoimmune disorders to cancer. We believe that we can deliver the next generation of biologic therapeutics to help improve the lives of millions of people.